by Carla K. Johnson Surgical instruments and supplies lay on a table during a kidney transplant surgery at MedStar Georgetown University Hospital in Washington D.C., Tuesday, June 28, 2016. Credit: AP Photo/Molly Riley, File People with HIV who need a kidney or liver transplant will be able to receive an organ from a donor with...
Tag: <span>HIV</span>
Post
Promising tuberculosis therapy safe for patients with HIV, finds study
October 1, 2024 by Texas Biomedical Research Institute Researchers compare the impacts of cART by itself versus cART plus the IDO inhibitor in lung tissue of nonhuman primates with both TB and SIV. Left: Following just cART, significantly more IDO is detected in pink. Right: With the IDO inhibitor and cART, immune cells recruited to...
Post
Trial finds metabolic risk contributes to diabetes onset in people with HIV
For people with HIV (PWH) with low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk, metabolic risk factors contribute to new-onset diabetes mellitus (DM) among those treated with pitavastatin or placebo, according to a study published online Oct. 8 in the Annals of Internal Medicine. Kathleen V. Fitch, from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues examined...
Post
New study increases understanding of HIV drug’s negative effects on the brain
News Release 17-Sep-2024 Findings pave the way toward mitigating some drugs’ toxic effects Peer-Reviewed PublicationUniversity of Maryland Baltimore County image: This is figure 4 from a paper in ACS Pharmacology & Translational Science that used a novel approach to show changes in lipid metabolism and protein expression as a result of treatment with the HIV...
Post
Twice-yearly injection cuts HIV risk by 96%, but will cost cut access?
September 13, 2024 by Ernie Mundell It could be a real breakthrough for people at risk for HIV infection: A shot given every six months that reduces their risk by a whopping 96%. That’s according to new trial results released Thursday by Gilead Sciences, which is repurposing its HIV treatment, the antiviral lenacapavir, as a...
Post
Diabetes drug helps the immune system recognize reservoirs of HIV, study discovers
September 10, 2024 by Bruno Geoffroy, University of Montreal Hospital Research Centre Graphical abstract. Credit: iScience (2024). DOI: 10.1016/j.isci.2024.110670Metformin, a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it entirely in people living with HIV who receive antiretroviral therapy, Canadian researchers say in a new study. In 2021,...
Post
7 ways to manage HIV medication side effects
Medications for HIV have many side effects and can make it challenging to continue treatment. Learn how to manage the side effects to ensure successful treatment and maintain quality of life. Although HIV remains incurable, various medications are available to help people living with HIV live longer, healthier lives and reduce the likelihood of virus...
Post
Experimental drug shows promise in clearing HIV from brain
July 26, 2024 by Tulane University Phosphorylation activation of CSF1R is increased with simian immunodeficiency virus. Credit: Brain (2024). DOI: 10.1093/brain/awae153An experimental drug originally developed to treat cancer may help clear HIV from infected cells in the brain, according to a new Tulane University study. For the first time, researchers at Tulane National Primate Research...
Post
Proof-of-concept study finds HIV-like virus particle could end need for need for lifelong medications
JULY 24, 2024 by George Mason University Development of the SIV Rev-dependent vectors to target SIV reservoirs. Credit: Gene Therapy (2024). DOI: 10.1038/s41434-024-00467-9Researchers in George Mason University’s Center for Infectious Disease Research (CIDR) and Tulane National Primate Research Center have conducted a breakthrough proof-of-concept study, published in the journal Gene Therapy, that found an HIV-like...
Post
Long-acting injectable ART superior to standard care for poorly adherent people with HIV
by Elana Gotkine For people with HIV (PWH) and a history of suboptimal adherence to antiretroviral therapy, long-acting injectable treatment with cabotegravir and rilpivirine (LAI) is superior to oral standard of care (SOC), according to a study presented at the annual Conference on Retroviruses and Opportunistic Infections, held from March 3 to 6 in Denver....